Long-Term Evaluation of Recurrence after Photodynamic Therapy with Topical Methyl Aminolevulinate for Non-Melanoma Skin Cancer: a Hospital-Based Study

Introduction & Objectives: Several factors may influence the decision to pursue nonsurgical modalities for the treatment of non-melanoma skin cancer. Topical photodynamic therapy (PDT) is a non-invasive alternative treatment reported to have a high efficacy when using standardized protocols in Bowen’s disease (BD), superficial basal cell carcinoma (BCC) and in thin nodular BCC. However, long-term recurrence studies are lacking. The aim of this study was to evaluate the long-term efficacy of PDT with topical methylaminolevulinate (MAL) for the treatment of BD and BCC in a dermato-oncology department. Materials & Methods: All patients with the diagnosis of BD or BCC, treated with MAL-PDT from the years 2004 to 2008, were enrolled. Treatment protocol included two MAL-PDT sessions one week apart repeated at three months when incomplete response, using a red light dose of 37-40 J/cm2 and an exposure time of 8’20’’. Clinical records were retrospectively reviewed, and data regarding age, sex, tumour location, size, treatment outcomes and recurrence were registered. Descriptive analysis was performed using chi square tests, followed by survival analysis with the Kaplan-Meier and Cox regression models. Results: Sixty-eight patients (median age 71.0 years, P25;P75=30;92) with a total of 78 tumours (31 BD, 45 superficial BCC, 2 nodular BCC) and a median tumour size of 5 cm2 were treated. Overall, the median follow-up period was 43.5 months (P25;P75=0;100), and a total recurrence rate of 33.8% was observed (24.4 % for BCC vs. 45.2% for BD). Estimated recurrence rates for BCC and BD were 5.0% vs. 7.4% at 6 months, 23.4% vs. 27.9% at 12 months, and 30.0% vs. 72.4% at 60 months. Both age and diagnosis were independent prognostic factors for recurrence, with significantly higher estimated recurrence rates in patients with BD (p=0.0036) or younger than 58 years old (p=0.039). The risk of recurrence (hazard ratio) was 2.4 times higher in patients with BD compared to superficial BCC (95% CI:1.1-5.3; p=0.033), and 2.8 times higher in patients younger than 58 years old (95% CI:1.2-6.5; p=0.02). Conclusions: In the studied population, estimated recurrence rates are higher than those expected from available literature, possibly due to a longer follow-up period. To the authors’ knowledge there is only one other study with a similar follow-up period, regarding BCC solely. BD, as an in situ squamous cell carcinoma, has a higher tendency to recur than superficial BCC. Despite greater cosmesis, PDT might no be the best treatment option for young patients considering their higher risk of recurrence.

Benefícios da Terapêutica de Ressincronização Cardíaca na «Miocardiopatia Muito Dilatada»

INTRODUCTION: Recent clinical trials have studied parameters that could predict response to cardiac resynchronization therapy (CRT) in patients with advanced heart failure. Left ventricular end-diastolic dimension (LVEDD) is regarded as a possible predictor of response to CRT. OBJECTIVE: To study the response to CRT in patients with very dilated cardiomyopathy, i.e. those at a more advanced stage of the pathology, analyzing both the responder rate and reverse remodeling in two groups of patients classified according to LVEDD. METHODS: We performed a retrospective analysis of 71 patients who underwent CRT (aged 62 +/- 11 years; 65% male; 93% in NYHA functional class > or = III; 31% with ischemic cardiomyopathy; left ventricular ejection fraction [LVEF] 25.6 +/- 6.8%; 32% in atrial fibrillation; QRS 176 +/- 31 ms). Twenty-two (31%) patients with LVEDD > or = 45 mm/m2 (49.2 +/- 3.5 mm/m2) were considered to have very dilated cardiomyopathy (Group A) and 49 patients had LVEDD > 37 mm/m2 and < 45 mm/m2 (39.4 +/- 3.8 mm/m2) (Group B). All patients were assessed by two-dimensional echocardiography at baseline and six months after CRT. The following parameters were analyzed: NYHA functional class, LVEF and LVEDD. Responders were defined clinically (improvement of > or = 1 NYHA class) and by echocardiography, with a minimum 15% increase over baseline LVEF combined with a reduction in LVEDD (reverse remodeling). RESULTS: There were no significant differences in baseline demographic characteristics between the two groups. At six-month followup, we observed an improvement in LVEF (delta 8.5 +/- 11.8%) and a reduction in LVEDD (delta 3.7 +/- 6.8 mm/m2), with fifty-seven (79%) patients being classified as clinical responders. The percentage of patients with reverse remodeling was similar in both groups (64% vs. 73%, p = NS), as were percentages of improved LVEF (delta 6.3 +/- 11% vs. delta 9.6 +/- 12%; p = NS) and decreased LVEDD (delta 3.7 +/- 5.5 mm/m2 vs. delta 3.7 +/- 7.4 mm/m2; p = NS). We found a higher percentage of clinical responders in patients with very dilated cardiomyopathy (96% vs. 72%, p < 0.05). CONCLUSION: In this study, a significant number of responders showed reverse remodeling after CRT. Although a higher percentage of patients with very dilated cardiomyopathy showed improvement in functional class, the extent of reverse remodeling was similar in both groups.

Existem Diferenças nos Resultados da Angioplastia Directa no Sexo Feminino?

Introdução: Em doentes com enfarte agudo do miocárdio (EAM), a angioplastia percutânea (ACTP) é de forma crescente aceite como a terapêutica de reperfusão mais eficaz. No sexo feminino estão descritos factores com implicação prognóstica na evolução do EAM. Existem diferenças detectáveis de morbilidade e mortalidade, após ACTP directa, no sexo feminino? Objectivos: Avaliar o perfil clínico e os resultados, em termos de morbilidade e mortalidade intrahospitalar, em mulheres submetidas a angioplastia directa por síndrome coronário agudo (SCA) com supradesnivelamento do segmento ST. Metodologia: Análise retrospectiva de 245 doentes consecutivos, 72 dos quais do sexo feminino (29,4 %), admitidos entre Janeiro de 2000 a Dezembro de 2001 por SCA com supradesnivelamento do segmento ST e submetidos a ACTP directa. Avaliámos a prevalência dos vários factores de risco cardiovascular – hipertensão arterial (HTA), tabagismo, dislipidémia, diabetes mellitus, história familiar –; antecedentes pessoais de angina, EAM e angioplastia prévios; horas de evolução do enfarte; características angiográficas e evolução clínica.Resultados: Do estudo descritivo dos dados, verificou-se que os doentes do sexo feminino eram mais idosos (67,9 ± 11,6 vs 59,6 ± 13; p < 0,001), com maior prevalência de HTA (65,3% vs 47,4 %; p < 0,05) e angina (29,0% vs 16,0 %; p < 0,05) e menor prevalência de tabagismo (27,8% vs 54,3 %; p < 0,001). A demora média (horas) entre o início da sintomatologia e a ACTP foi significativamente maior nas mulheres (6,8 ± 4,1 vs 5,4 ± 3,7; p < 0,05). Angiograficamente, o número de lesões existentes e abordadas foi semelhante nos dois grupos. Utilizaram-se inibidores da glicoproteína IIb/IIIa em 84,7% das mulheres e 90,8% dos homens. Dos eventos considerados, verificou-se maior ocorrência de complicações hemorrágicas minor (5,6% vs 5,2 %), arritmias (15,3% vs 10,4 %) e mortalidade intrahospitalar (9,7% vs 6,4 %) no sexo feminino, sem no entanto apresentar significado estatístico. A demora média intra- -hospitalar foi semelhante nos dois grupos. Conclusão: Apesar da crescente preocupação com a homogeneidade de abordagens diagnósticas e terapêuticas nos dois sexos, particularmente no acesso a terapêutica de reperfusão, a morbilidade e mortalidade são tendencialmente superiores na nossa população, sem contudo atingir significado estatístico. A idade mais avançada e a maior demora até à realização da angioplastia, podem explicar esta discrepância.

Recidiva de Cancro Cutâneo Não-Melanoma após Terapêutica Fotodinâmica num Serviço de Dermatologia

Introdução: São escassos os estudos de eficácia a longo prazo da terapêutica fotodinâmica(TFD) no tratamento da doença de Bowen (DB) e do carcinoma basocelular (CBC). Objectivos: Determinar a eficácia a longo prazo da TFD com metilaminolevulinato (MAL) no tratamento da DB e do CBC pela análise de recidiva. Material e método: Foram analisados retrospectivamente os processos clínicos de doentes com o diagnóstico de DB ou CBC tratados com TFD-MAL num serviço de Dermato- Oncologia entre 2004 e 2008. Foi efectuada a análise descritiva dos dados pelo teste do chiquadrado, seguida da análise de sobrevivência pelos métodos de Kaplan-Meier e regressão de Cox. Resultados: Foram tratados 68 doentes (mediana etária 71 anos, P25;P75=30;92) com um total de 78 tumores (31 DB, 45 CBC superficiais, 2 CBC nodulares finos). No período de seguimento efectuado (mediana 43,5 meses, P25;P75=0;100) observou-se uma taxa de recidiva de 25% no CBC e 45,2% na DB. As taxas de recidiva estimadas para os CBC e DB foram de 5,0% vs. 7,4% aos 6 meses, 23,4% vs. 27,9% aos 12 meses e de 30,0% vs. 72,4% aos 60 meses. Idade e diagnóstico constituíram factores independentes de prognóstico, com taxas de recidiva significativamente maiores nos doentes com DB (p=0,0036) ou com menos de 58 anos (p=0,039). De modo semelhante, o risco de recidiva foi 2,4 vezes superior nos doentes com DB face àqueles com CBC (p=0,033) e 2,8 vezes maior em doentes com menos de 58 anos (p=0,02). Conclusões: Na população estudada, a taxa de recidiva foi superior àquela encontrada na literatura. A TFD pode não ser a melhor opção para o tratamento do cancro cutâneo nãomelanoma em doentes mais jovens, em particular na doença de Bowen. Apesar do melhor resultado cosmético, o risco de recidiva deve ser equacionado e a escolha terapêutica deve ser ponderada caso a caso.

Safety and Effectiveness of the Genous Endothelial Progenitor Cell-Capture Stent: Follow-Up to 5 Years

AIMS: To evaluate the long-term clinical outcomes following percutaneous coronary intervention (PCI) with the Genous stent in an unselected population. METHODS: All patients admitted to a single center who underwent PCI using the GS exclusively, between May 2006 and May 2012, were enrolled, and a clinical follow-up of up to 60 months was carried out. The primary endpoint of major adverse cardiac event (MACE) rate was defined as the composite of cardiac death, acute myocardial infarction (AMI), and target lesion revascularization (TLR). RESULTS: Of the 450 patients included (75.1% male; 65.5 ± 11.7 years), 28.4% were diabetic and acute coronary syndrome was the reason for PCI in 76.4%. Angioplasty was performed in 524 lesions using 597 Genous stents, with angiographic success in 97.1%. At a median of 36 months of follow-up (range, 1-75 months), MACE, AMI, TLR, stent restenosis (SR), and stent thrombosis (ST) rates were 15.6%, 8.4%, 4.4%, 3.8%, and 2.2%, respectively. Between 12 and 24 months, the TLR, SR, and ST rates practically stabilized, up to 60 months. Bifurcation lesions were independently associated with MACE, TLR, and SR. CONCLUSION: This is the first study reporting clinical results with the Genous stent up to 60 months. The Genous stent was safe and effective in the long-term, in an unselected population.

Evidence for Nevirapine Bioactivation in Man: Searching for the First Step in the Mechanism of Nevirapine Toxicity

Despite its efficacy, including in the prevention of vertical transmission, the antiretroviral nevirapine is associated with severe idiosyncratic hepatotoxicity and skin rash. The mechanisms underlying nevirapine toxicity are not fully understood, but drug bioactivation to reactive metabolites capable of forming stable protein adducts is thought to be involved. This hypothesis is based on the paradigm that drug reactive metabolites have the potential to bind to self-proteins, which results in drug-modified proteins being perceived as foreign by the immune system. The aim of the present work was to identify hemoglobin adducts in HIV patients as biomarkers of nevirapine haptenation upon bioactivation. The ultimate goal is to develop diagnostic methods for predicting the onset of nevirapine-induced toxic reactions. All included subjects were adults on nevirapine-containing antiretroviral therapy for at least 1month. The protocol received prior approval from the Hospital Ethics Committees and patients gave their written informed consent. Nevirapine-derived adducts with the N-terminal valine of hemoglobin were analyzed by an established liquid chromatography-electrospray ionization-tandem mass spectrometry method and characterized on the basis of retention time and mass spectrometric fragmentation pattern by comparison with adduct standards prepared synthetically. The nevirapine adducts were detected in 12/13 patient samples, and quantified in 11/12 samples (2.58±0.8 fmol/g of hemoglobin). This work represents the first evidence of nevirapine-protein adduct formation in man and confirms the ability of nevirapine to modify self-proteins, thus providing clues to the molecular mechanisms underlying nevirapine toxicity. Moreover, the possibility of assessing nevirapine-protein adduct levels has the potential to become useful for predicting the onset of nevirapine-induced adverse reactions.

Complicações Hipertensivas na Gravidez. 1 Mês na Maternidade Dr. Alfredo da Costa

A patologia hipertensiva ocorre em 6 a 8% das gravidezes e é a segunda causa de morte materna, contribuindo com 15% para essa taxa de mortalidade. É também causa significativa de morte fetal e morbi-mortalidade neonatal. O objectivo deste trabalho foi avaliar, através de uma análise retrospectiva, as complicações hipertensivas na população de grávidas que tiveram o parto na Maternidade Dr. Alfredo da Costa (MAC) em Novembro de 2005. Durante este período 41 mulheres (10,1%) tiveram complicações hipertensivas. Treze grávidas (31,7%) tinham hipertensão crónica, dezanove (46,3%) HIG, 5 (12,2%) PE moderada e 7 (17%) PE grave, com 3 casos de síndrome HELLP. Registou-se um caso de síndrome HELLP sem hipertensão arterial. Registaram-se 9 casos de parto prematuro (22,5%) e uma morte fetal. A idade gestacional média foi 37 semanas. Assinalaram-se 9,7% de RCIU e nenhum caso de asfixia neonatal.

Insuficiência Pulmonar Valvular Congénita

Descrevem-se 4 casos de Insuficiência Pulmonar Valvular Congénita com septo interventricular intacto em crianças de sexo masculino com idades compreendidas entre os 20 meses e os 10 anos, na 1a observação na Consulta de Cardiologia Pediátrica. 0 diagnóstico clínico de regurgitação pulmonar foi confirmado por electrocardiograma, fonocardiograma e radiografia de tórax em todos os doentes e também por ecocardiograma, exame hemodinâmico e angiocardiográfico em 3 deles. Após um follow-up que variou entre 1 e 9 anos, média 5 anos e 2 meses, concluiu-se que a Insuficiência Pulmonar Valvular Congénita, como cardiopatia isolada, é bem tolerada em idades pediátricas e compatível com desenvolvimento físico e actividade normais.

Renal Transplantation in HIV-Infected Patients: The First Portuguese Review

INTRODUCTION: With the introduction of combination antiretroviral therapy (cART), prognosis of human immunodeficiency virus (HIV) infection has been improved and kidney transplantation (KT) in HIV-positive patients became possible. METHODS: We reviewed the demographic, clinical, laboratory, and therapeutic data of all the HIV-infected patients who underwent KT between 2009 (first KT in Portugal in a HIV-infected patient) and May 2014. Case accrual was through all Portuguese KT centers where a KT in an HIV-infected patient was performed. Patients were transplanted following the American and Spanish guideline recommendations that included maintenance on cART, undetectable plasma HIV RNA copies, and absolute CD4 counts of ≥ 200 cells/μL in the last 6 months. RESULTS: Fourteen KT were performed on men and 3 on women. The mean age of patients at the time of transplantation was 49.9 ± 11.7 years. HIV status was known for 12 ± 5 years. Eight patients had AIDS in the past and all patients received grafts from deceased donors. Twelve patients (64.7%) underwent induction therapy with basiliximab and 2 patients experienced early graft loss. In 2 patients, humoral rejection was diagnosed and in 3 patients, cellular rejection. Two patients died and an additional patient had early graft loss. CONCLUSION: KT is a possible, but challenging, renal replacement therapy in selected HIV-positive patients. Even in those with AIDS criteria in the past, when the disease is controlled, and after the reconstitution of the immune system with cART, KT can be performed. Nevertheless, the risk-benefit ratio for each patient needs to be taken in consideration.